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Abstract
The purpose of this study was to test the feasibility of undertaking a full population investiga-
tion into the prevalence, incidence, and persistence of oral Human Papilloma Virus (HPV) in
Scotland via dental settings. Male and female patients aged 16–69 years were recruited by
Research Nurses in 3 primary care and dental outreach teaching centres and 2 General
Dental Practices (GDPs), and by Dental Care Teams in 2 further GDPs. Participants com-
pleted a questionnaire (via an online tablet computer or paper) with socioeconomic, lifestyle,
and sexual history items; and were followed up at 6-months for further questionnaire through
appointment or post/online. Saline oral gargle/rinse samples, collected at baseline and fol-
low-up, were subject to molecular HPV genotyping centrally. 1213 dental patients were
approached and 402 individuals consented (participation rate 33.1%). 390 completed the
baseline questionnaire and 380 provided a baseline oral specimen. Follow-up rate was
61.6% at 6 months. While recruitment was no different in Research Nurse vs Dental Care
Team models the Nurse model ensured more rapid recruitment. There were relatively few
missing responses in the questionnaire and high levels of disclosure of risk behaviours
(99% answered some of the sexual history questions). Data linkage of participant data to
routine health records including HPV vaccination data was successful with 99.1% matching.
Oral rinse/gargle sample collection and subsequent HPV testing was feasible. Preliminary
analyses found over 95% of samples to be valid for molecular HPV detection prevalence of
oral HPV infection of 5.5% (95%CI 3.7, 8.3). It is feasible to recruit and follow-up dental
patients largely representative / reflective of the wider population, suggesting it would be
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Introduction
Oropharyngeal (throat) cancer (OPC) is among the cancers with the fastest increasing inci-
dence in the UK, with a near 3-fold rise in the past 15 years and incidence rates around 5 per
100,000 [1, 2, 3]. These trends are a global phenomenon—described as an epidemic in North
America [4], with rapid increases also observed in Central Europe and South America follow-
ing behind this curve [5]. Around 60% of OPC is associated with oral Human Papillomavirus
(HPV) infection; likely acquired from genital HPV infection during oral sexual behaviour,
with smoking also a strongly associated risk factor [6, 7].
HPV infection is increasingly implicated in the rising incidence of OPC [8], with HPV types
16/18 responsible for almost all HPV-positive cases of OPC [9]. The natural history of oral
HPV infection—including prevalence, incidence, determinants and risk factors—is relatively
unknown. To date, the only large population-based study of oral HPV prevalence has been
undertaken in the United States of America [10]. This cross-sectional study (n = 5579) found an
overall population prevalence of 6.9% and a bimodal increasing pattern with age—a prevalence
of over 7% among those in their 20s and 30s, and a further peak of over 11% in those in their
50s and early 60s. Another cohort (n = 1688) of men from across the Americas found an overall
prevalence of 4% [11] and 4.4% incident oral HPV infections in 12 months [12], and a small
cohort (n = 212) of male university students in the USA reported a prevalence of 7.5% [13]. An
earlier systematic review of 18 cancer case-control studies worldwide found an overall preva-
lence of 4.5% oral HPV infection in healthy individuals (cancer-free control subjects) [14].
There have been only two European studies, both small. In the first, a 9.3% prevalence was
found in a Swedish sexual health clinic-based study (n = 483), of adults aged 15–23 years, with
reported high cervical HPV prevalence (70%) among the female participants (n = 408) [15]. In
the second, a 1.2% prevalence was reported in a small sample (n = 81) study of hospital outpa-
tients in Italy, aged 49–77 years [16].
Oral HPV prevalence or incidence have rarely been investigated in relation to HPV vacci-
nation. One proof-of-principle study demonstrated the prevention potential of the HPV
vaccination against oral HPV infection [17]. A recent follow-up study of the aforementioned
Swedish study found a substantial decrease in oral HPV prevalence to 1.4% in 2013–14 from
9.3% in 2009–11 following the introduction of HPV vaccination between 2007 and 2014 [18].
The National HPV Immunisation Programme in Scotland began in 12–13 year old females
in 2008 as an intervention to reduce cervical cancer. Uptake of the HPV vaccine has been
impressive, with sustained high levels of coverage (>90%) and a catch-up campaign, running
over 3 years, which offered vaccination to all females aged 13–18 years old with an uptake of
66% [19]. It is feasible that the immunisation programmes will have an impact on infection
and disease beyond those recently demonstrated for the anogenital tract [20]. However, there
are no routine data on the population-based incidence and prevalence of oral HPV, nor on the
impact of immunisation on oral infection or herd immunity in males.
The primary aim of the HOPSCOTCH project was to test the feasibility of using dental set-
tings, to undertake a population-wide (16–69 years) epidemiological study of the incidence,
prevalence, and determinants of oral HPV infection in the Scottish population, which could
ultimately allow assessment of the impact of the HPV vaccination programme in Scotland on
HPV Oral Prevalence in Scotland (HOPSCOTCH)
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oral HPV infection in young women and potential herd immunity in men aged 16–25 years
old. The specific objectives of the study were to assess the feasibility and best methods of
recruiting dental patients and capturing complete questionnaire data (including sexual his-
tory); and to examine the practical / logistical aspects of taking and transferring oral gargle/
rinse samples from the dental facility to the Scottish HPV Reference Laboratory in a state suit-
able for assay. NHS dental facilities (including dental practices and dental outreach teaching
centres) in Scotland are potentially ideal settings for this study as patients are generally healthy,
attend regularly for routine dental appointments [21], and the oral gargle/rinse method of
specimen collection is in-keeping with dental clinical activities. Dental teams also have a
potential role in tackling rising oral/oropharyngeal cancer trends through prevention and
early detection [22]. Moreover, Scotland is particularly well placed to conduct this research
given the robust national health datasets and data linkage potential at the individual patient
level, allowing individual vaccination histories to be obtained [19, 23].
Methods
Recruitment
Baseline recruitment commenced in November 2013 and continued to March 2015. Potential
outreach teaching centres and General Dental Practitioners (GDPs) registered with the Scot-
tish Dental Practice Based Research Network (SDPBRN) as Rapid Evaluation Practices (REPs)
were sent a Study Information Sheet and invitation letter and subsequently contacted by tele-
phone to confirm suitability for participation. All potential sites were assessed for suitability
regarding their geographical location, patient numbers/profile, wi-fi/internet accessibility and
availability of private space. Baseline patient recruitment and data collection took place in
seven sites (three outreach teaching centres and four GDPs). We tested recruitment and data
collection conducted by Research Nurses in five sites (initially two, but extended to three out-
reach teaching centres and two GDPs) versus recruitment and data collection conducted
entirely by the dental practice clinical team (in two further practices). Sites were based in NHS
Greater Glasgow & Clyde (GG&C) and NHS Tayside Health Boards (S1 File). Relevant person-
nel, including Research Nurses and Dental Care Teams from all participating sites, were pro-
vided with study-specific training, including how to handle queries and concerns raised by the
questionnaire topics. Dental practice participation costs for each of the two models were devel-
oped based on similar items of service on the NHS Scotland primary care dental contract and
were set in agreement with participating dentists as a reasonable fee for the tasks (S2 File).
A paper-based participation/screening log was used to record the details of all patients
screened for eligibility. Screened patients were either: i) sent the study invitation materials
(invitation letter, Participant Information Sheet—which included the information that we
would not be providing participants with the results of the HPV test) two weeks prior to rou-
tine dental appointment; or ii) given the materials at the time of appointment, provided this
was at least 30 minutes ahead of the approach for potential recruitment to the study. The
method of approach varied by site, related to local patient appointment processes. Participat-
ing patients were assigned a study identification number and contact information was stored
for the 6-month follow-up. For non-participants, reasons for non-participation, age, sex and
home postcode (to assign the area-based socioeconomic deprivation index score—Scottish
Index Multiple Deprivation (SIMD) [24])–were logged.
Informed consent was sought by Research Nurses at five sites, and by a trained Dental
Nurse from the Dental Care Team at two sites. Consent was sought for study participation
(including 6-month follow-up), specimen storage in the Scottish HPV Archive (Edinburgh),
participation in data linkage, and willingness to be approached to participate in future studies.
HPV Oral Prevalence in Scotland (HOPSCOTCH)
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We developed a bespoke, web-based questionnaire with the University of Glasgow Robert-
son Centre for Biostatistics (RCB). Responses were stored directly onto the RCB secure servers.
Participants self-completed the questionnaire via an online tablet computer in a private area
(paper versions were also available where needed—S3 File—female questionnaire and S4 File
—male questionnaire). Items were based on previous studies in the field [10], along with the
National Survey of Sexual Attitudes and Lifestyles (NATSAL) [25] and the Scottish Health Sur-
vey [26]. These included demographics (age, gender, ethnicity, socioeconomic status), lifestyle
behaviours (use of tobacco, alcohol and other recreational drugs), oral health and dental care,
sexual behaviour history / health, and history of HPV vaccination.
Follow-up at 6-months
Participants were invited to provide follow-up data 6-months after baseline in one of the three
following ways:
1. Participants recruited via the Research Nurse model were followed up via specific study
appointment sessions. All follow-up activities were conducted by a Research Nurse. Partici-
pants were reimbursed for travel costs.
2. Participants recruited via the GDP model were followed up via return to the general dental
practice setting at routine 6 monthly dental recall appointments. Follow-up activities were
conducted by the Dental Care Team.
3. The final one-third (sequentially) of all participants (both recruitment models) was fol-
lowed up via a postal/online questionnaire, with self-administration of the oral gargle/rinse
and posting of the sample. Those who failed to attend their follow-up appointment were
also offered this option.
Data-linkage
The study examined the feasibility of successfully linking patient participant data to routine
health datasets. A unique identifier relating to each participant who consented to record link-
age to national datasets, including the Scottish Immunisation & Recall System (SIRS) and
Child Health Schools Programme-System (CHSP-S) for HPV vaccination data, was assigned
to both his/her consent form and questionnaire. Data linkage was performed by the Electronic
Data Research and Innovation Service (eDRIS), Information Services Division, NHS National
Services Scotland.
Oral gargle/rinse specimen collection
Participants provided a bio specimen comprising a 10 ml oral rinse sample in saline mouth
rinse at two time points, 6 months apart [10, 25]. Participants performed the oral gargle/rinse
for 30 seconds in total—timed on a timer application on the tablet computer. Specimens were
sealed, labelled with the participant identifier and stored at room temperature or in a fridge
until they were transported to the Scottish HPV Reference Laboratory (SHPVRL) for process-
ing, nucleic acid (NA) extraction and molecular HPV testing.
Specimen processing / testing
Cell pellets were obtained from 10 ml rinses via centrifugation at 2900 ± 150 X g for 15 ± 2
mins., supernatants were discarded and the cellular pellets frozen in tissue stabilisation buffer
(Qiagen, Manchester UK) pending NA extraction. NA was extracted using a system initially
HPV Oral Prevalence in Scotland (HOPSCOTCH)
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optimised for downstream HPV detection of cervical and urine samples [13] using the Qiagen
Media Kit (Qiagen, Manchester, UK) on the MDX Platform. Yield and quality of NA were
measured by spectrophotometry (260/280 ratios). Residual extracts after HPV genotyping
were stored in the Scottish HPV Archive (http://www.shine.mvm.ed.ac.uk/archive.shtml) for
use in anonymised research in the future.
HPV genotyping
HPV amplification and genotyping were performed using a luminex based HPV genotyping
assay, currently used for national HPV immunisation surveillance [27, 28]. This assay is based
on amplification of a short fragment of the HPV L1 region, and delineates up to 24 high and
low risk HPV types (including those types covered by the vaccine). It also incorporates a beta
globin control for cellularity. HPV type specific prevalence was analysed descriptively.
Statistical analysis of participant data was carried out using R version 3.1.1. Confidence
intervals for the participation proportions, follow-up rates and HPV positivity percentages
were calculated using Wilson’s method using the Hmisc package in R. 95% confidence inter-
vals are reported in all cases. Chi square tests were used to test for associations between the
outcomes and demographic variables. Simulation tests based upon 5000 replications were
used to calculate the p values. Post stratification weights were estimated using raking to adjust
the HPV prevalence to address any imbalance between sample and population demographics.
This was carried out using the survey package in R.
Ethics statement
NHS West of Scotland Research Ethics Committee (REC) specifically approved this study
[Reference no. 13/WS/0166:19/09/13], and NHS National Services Scotland Privacy Advisory
Committee (PAC) [PAC37/14:4/02/15] approved the data linkage.
Results
Participation rates
A total of 1212 individuals, aged 16–69, were approached to take part in the study from seven
centres in two health board areas—NHS GG&C and NHS Tayside. Of these, 59% were female
compared to the Scottish population of which 51% in this age-group are female [29]. The age
distribution among the individuals who were approached was also an under-representation of
those in the 16–25 age group (12% of those approached and 19% of population) and the 26–39
age group (20% of those approached and 25% of the population). There is a corresponding
slight over-representation in the older ages (Table 1).
In total, 402 individuals agreed to participate in the study giving an overall participation
rate of 33.1% with no imbalance in participation rates between men and women. Among the
1072 with known age, participation was significantly associated with age (p = 0.010) and was
lower among those aged 16–25. There was no apparent association (p = 0.827) with participa-
tion and SIMD (Table 1).
There were significant differences among the participation rates according to research site
—(p<0.0001), with relatively low participation in two centres (GDP1 –Tayside, and outreach
teaching 1 –Tayside). Participation was not significantly (p = 0.072) associated with the
use of a Research Nurse as opposed to a Dental Care Team. Similarly, it was not associated
(p = 0.432) with the type of dental setting (Table 1). Reasons for non-participation were docu-
mented for 81% of the 811 non-responders (Table 2). The main reason noted for non-partici-
pation was patient refusal (31.6%).
HPV Oral Prevalence in Scotland (HOPSCOTCH)
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Table 1. Participation rates by demographic and research model characteristics.
Variable Category Approached n Participated n % 95% CI
Overall 1212 402 33.2 30.6 35.9
Gender Male 502 161 32.1 28.1 36.3
Female 710 241 33.9 30.6 37.5
Age 16–25 146 42 28.8 22.0 36.6
26–39 245 106 43.3 37.2 49.5
40–49 255 84 32.9 27.5 38.9
50–59 243 90 37.0 31.2 43.3
60–69 183 80 43.7 36.7 51.0
Missing 140 0 0.0 0.0 2.7
SIMD 1 (most deprived) 280 90 32.1 26.9 37.8
2 157 59 37.6 30.4 45.4
3 177 61 34.5 27.9 41.7
4 279 92 33.0 27.7 38.7
5 (least deprived) 265 90 34.0 28.5 39.9
Incomplete Postcode 40 6 15.0 7.1 29.1
Missing Postcode 14 4 28.6 11.7 54.6
Centre Teaching/outreach 1—Tayside 102 17 16.7 10.7 25.1
GDP 1—Tayside 176 34 19.3 14.2 25.8
GDP 2—Tayside 268 104 38.8 33.2 44.8
Teaching/outreach 1—GG&C 369 130 35.2 30.5 40.2
GDP 1—GG&C 167 60 35.9 29.0 43.4
GDP 2—GG&C 101 45 44.6 35.2 54.3
Teaching/outreach 2—Tayside 29 12 41.4 25.5 59.3
Recruitment model Research Nurse 935 323 34.5 31.6 37.7
Dental Team 277 79 28.5 23.5 34.1
Setting Teaching/outreach 500 159 31.8 27.9 36.0
General Dental Practice (GDP) 712 243 34.1 30.7 37.7
n—number; CI—Confidence Interval; SIMD—Scottish Index of Multiple Deprivation; GDP—General Dental Practice; GG&C—Greater Glasgow & Clyde
doi:10.1371/journal.pone.0165847.t001
Table 2. Reasons for non-participation.
Reason for Non Participation n %
Did not want to participate 256 31.6
Did not attend appointment 132 16.3
Did not have time 107 13.2
Did not receive Patient Information Sheet 43 5.3
Dentist refused 7 0.9
Inability to read English 5 0.6
Did not want to complete questionnaire 4 0.5
Concerned about NOT receiving HPV test results 2 0.2
Did not want to complete oral rinse/gargle 2 0.2
Did not want to commit to 6-month follow-up 1 0.1
Other 96 11.8
Not Known 156 19.2
Total 811
doi:10.1371/journal.pone.0165847.t002
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Of those who had agreed to participate (n = 402): (a) all participants had initialled the
box on the consent form indicating they had understood the Participant Information Sheet
and agreed to participate in the baseline and 6-month follow-up; (b) 16 (3.9%) did not give
consent for the data linkage element of the study; (c) 23 (5.7%) participants did not wish to be
contacted about future studies. The Research Nurse model was more effective in terms of
achieving the target recruitment numbers on time in three of the four sites (26 recruiting
weeks, 30 calendar weeks), while the Dental Care Team model did not reach the target despite
recruiting in almost twice the number of recruiting weeks (49 recruiting weeks, 55 calendar
weeks). The average cost per recruitment was substantially lower in the Dental Care Team
model (£26.23)–under half those associated with the Research Nurse (£66.46).
Questionnaire data
A total of 390 participants (from 402 who consented) completed the questionnaire (n = 210,
53.8% electronically, and n = 180, 46.2% on a paper version); 263 (67.4%) participants com-
pleted all 30 questions which should have been answered by everyone, 354 (90.8%) omitted
less than 2 questions. The most non-responses (12.1%) were for the income question
(Table 3). Only 7 (1.8%) participants did not answer the question about recreational drug use
(Table 4). Similarly there were low levels of missing data on the sexual health questions for
Table 3. Participant self-report sociodemographic characteristics.
Characteristic Number
Responding
Male
% (n = 158)
Female
% (n = 232)
Ethnicity White 383 93.5% (143) 95.7% (220)
Mixed 0.7% (1) 0.0% (0)
Asian; Asian Scottish or Asian British 2.6% (4) 2.2% (5)
African 1.3% (2) 1.3% (3)
Any other ethnicity 2.0% (3) 0.9% (2)
Missing n 5 2
Education level Primary School 377 0.0% (0) 0.9% (2)
Secondary School 15.5% (23) 21.8% (50)
Further Education/Technical College 39.2% (58) 29.7% (68)
University 40.5% (60) 40.6% (93)
Some other type of college 4.7% (7) 7.0% (16)
Missing n 10 3
Marital status Never married and never registered a same-sex civil partnership 370 28.9% (43) 34.8% (77)
Married 58.4% (87) 40.3% (89)
Separated but still legally married 2.0% (3) 5.4% (12)
Divorced 8.1% (12) 12.2% (27)
Widowed 1.3% (2) 4.5% (10)
In a registered same-sex civil partnership 1.3% (2) 2.7% (6)
Missing n 9 11
Annual income (£) Nil or loss 343 1.4% (2) 2.0% (4)
1-9,999 10.5% (15) 18.5% (37)
10k-19,999 20.3% (29) 26.5% (53)
20k-29,999 14.7% (21) 16.0% (32)
30k-39,999 19.6% (28) 13.5% (27)
>40k 33.6% (48) 23.5% (47)
Missing n 15 32
doi:10.1371/journal.pone.0165847.t003
HPV Oral Prevalence in Scotland (HOPSCOTCH)
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both men and women and there was only one woman who did not answer the HPV vaccina-
tion question. Most participants (99.0%) answered some of the sexual history questions, and
331–136 men / 195 women–(84.9%) answered all seven of the questions for men and all eight
for women (Table 5). While we had high responses to the sexual behaviour and health ques-
tions, 35.7% of males and 39.6% of females reported that they were uncomfortable with the
questions on sexual activity in feedback items at the end of the questionnaire.
The self-report vaccine data were comparable to the health administrative datasets. Data
linkage of our study data to the Community Health Index (CHI) number (the unique identifier
which is a population register used to register all patients in Scotland with a family doctor) was
successful on 99.7% (n = 384) of the 385 participants who’s data were submitted to ISD—all of
whom had consented for data linkage. For the purposes of preliminary feasibility, linkage to
the SIRS database was tested. Of the 375 individuals who completed the questionnaire and
linked to SIRS database, 15 had received the HPV vaccination (13 had all three doses, one had
two doses, and one had one dose). There were no HPV vaccination records for men in the
SIRS data. Among the 221 questionnaires from female participants, 18 reported having had
Table 4. Participant self-report lifestyle behaviours.
Behaviour Male
% (n = 158)
Female
% (n = 232)
Alcohol ever Current 382 85.2% (132) 86.3% (196)
Former 10.3% (16) 8.4% (19)
Never 4.5% (7) 5.3% (12)
Missing n 3 5
Alcohol frequency Monthly or less 357 19.7% (29) 32.9% (69)
2–4 times per month 19.7% (29) 34.8% (73)
2–3 times per week 40.1% (59) 19.5% (41)
4+ times per week 20.4% (30) 12.9% (27)
Missing n 11 22
Units per day 1–2 341 20.7% (29) 37.3% (75)
3–4 29.3% (41) 23.4% (47)
5–6 11.4% (16) 16.4% (33)
7–9 12.1% (17) 10.0% (20)
10+ 26.4% (37) 12.9% (26)
Missing n 18 31
> recommended units Never 349 20.5% (30) 31.0% (63)
Less than monthly 28.8% (42) 37.4% (76)
Monthly 19.2% (28) 18.7% (38)
Weekly 26.0% (38) 11.8% (24)
Daily or almost daily 5.5% (8) 1.0% (2)
Missing n 12 29
Smoking Yes 385 25.6% (40) 27.5% (63)
No 74.4% (116) 72.5% (166)
Missing n 2 3
Recreational drugs Yes 383 38.7% (60) 27.6% (63)
No 61.3% (95) 72.4% (165)
Missing n 3 4
Cannabis Yes 389 35.7% (56) 22.0% (51)
No 64.3% (101) 78.0% (181))
Missing n 1 0
doi:10.1371/journal.pone.0165847.t004
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Table 5. Participant self-report sexual behaviour and health history.
Behaviour Male
% (n = 158)
Female
% (n = 232)
Ever sex Yes 381 99.3% (152) 98.2% (224)
No 0.7% (1) 1.8% (4)
Missing n 5 4
Vaginal sex Yes 367 98.7% (147) 97.7% (213)
No 1.3% (2) 2.3% (5)
Missing n 8 10
Age first vaginal sex (years) <=15 336 20.0% (28) 15.8% (31)
16–20 62.9% (88) 73.0% (143)
>20 17.1% (24) 11.2% (22)
Missing n 17 32
No. vaginal sex partners <=2 322 16.3% (21) 34.7% (67)
3–5 21.7% (28) 29.0% (56)
6–10 27.9% (36) 19.2% (37)
>10 34.1% (44) 17.1% (33)
Missing n 28 35
Sexual history Only with females 375 93.2% (138) 0.0% (0)
More often with females 3.4% (5) 3.5% (8)
About equally often with females and males 0.7% (1) 0.0% (0)
More often with males 2.7% (4) 6.6% (15)
Only with males 0.0% (0) 88.1% (200)
Only ever with females and never with males 0.0% (0) 0.9% (2)
I have never had any sexual experience with anyone at all 0.0% (0) 0.9% (2)
Missing n 10 5
Oral sex with men Yes 366 5.3% (8) 89.3% (192)
No 94.7% (143) 10.7% (23)
Missing n 6 13
Oral sex with men no. of life partners 1 185 0.0% (0) 34.5% (61)
2 12.5% (1) 20.9% (37)
3–5 25.0% (2) 24.9% (44)
>5 62.5% (5) 19.8% (35)
Missing n 0 15
Oral sex with men no. of partners in past year 0 183 16.7% (1) 36.7% (65)
1 33.3% (2) 58.2% (103)
>1 50.0% (3) 5.1% (9)
Missing n 2 15
Oral sex with women Yes 374 90.7% (137) 6.3% (14)
No 9.3% (14) 93.7% (209)
Missing n 6 5
Oral sex with women no. of life partners <=2 138 33.1% (41) 71.4% (10)
3–5 32.3% (40) 14.3% (2)
>5 34.7% (43) 14.3% (2)
Missing n 13 0
Oral sex with women no. of partners in past year 0 140 23.8% (30) 42.9% (6)
1 63.5% (80) 50.0% (7)
>1 12.7% (16) 7.1% (1)
Missing n 11 0
(Continued )
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the HPV vaccine (16 reported having had all three doses, 2 had one or two doses), 202 reported
no HPV vaccine, with 1 missing value. Three women stated that they had the HPV vaccine (2
with all three doses and 1 with one or two doses) but there is no corresponding record in SIRS;
these three women were aged between 35–50 years and it is unlikely that they received the vac-
cine. Among the 21 women aged 16–25 there was an exact match between the questionnaire
and SIRS for 17. Of the remainder, one reported that she had received three doses but has only
one record in the SIRS data, and two stated that they had three doses but there is no record in
SIRS.
Follow-up at 6 months
Follow-up is primarily assessed among the 380 participants who had a valid baseline oral gar-
gle/rinse specimen, as the principal aim of the follow-up is in the determination of new/inci-
dent acquisitions of oral HPV among participants who were negative at baseline and clearance
of HPV among participants who were positive for HPV at baseline. Participants who had a fol-
low-up oral specimen submitted to SHPVRL were considered to have satisfied the conditions
for a successful follow-up. Overall follow-up rate was 61.6%, with similar rates among men and
women. Follow-up was significantly better among older patients (p<0.0001). There was no evi-
dence (p = 0.186) to suggest that follow-up was associated with deprivation of the participant
(Table 6). The evidence suggested that follow-up was better with Research Nurses (p = 0.023)
Table 5. (Continued)
Behaviour Male
% (n = 158)
Female
% (n = 232)
Anal sex with men Yes 366 4.7% (7) 24.1% (52)
No 95.3% (143) 75.9% (164)
Missing n 7 12
Anal sex with women Yes 149 36.2% (54)
No 63.8% (95)
Missing n 8
Sexually transmitted infection Yes 380 10.9% (17) 14.7% (33)
No 89.1% (139) 84.8% (190)
Don’t remember 0.0% (0) 0.4% (1)
Missing n 2 8
Genital warts Yes 382 7.1% (11) 7.0% (16)
No 92.2% (142) 91.7% (209)
Don’t remember 0.6% (1) 1.3% (3)
Missing n 4 4
HIV Test Yes 383 20.8% (32) 18.8% (43)
No 76.6% (118) 75.5% (173)
Maybe/not sure 2.6% (4) 5.7% (13)
Missing n 4 3
HIV Result Negative 75 96.9% (31) 100.0% (43)
Positive 3.1% (1) 0% (0)
Missing n 0 0
HPV Vaccine Yes (3 doses) 231 7.4% (17)
Yes (1/2 doses) 0.9% (2)
No 91.8% (212)
Missing n 1
doi:10.1371/journal.pone.0165847.t005
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with a rate of 64.3% compared to 48.5% with Dental Care Team model. Follow-up in GDPs
was slightly better than outreach teaching centres but not statistically different (p = 0.159). Fol-
low-up by appointment in either setting or by either recruitment model had substantially
higher (p<0.0001) follow-up success (86.6%) compared to postal follow-up (39.7%).
HPV testing process
Generally, operational processes between source collection points and the central testing labora-
tory were good with few significant issues. Of the samples received at SHPVRL, only 11 could
not be processed for HPV testing: 7/11 were discarded due to a packaging error where the transit
receptacle was used to contain the sample instead of the primary (inner) tube and 4/11 were
labelled inadequately. These issues related to 2 tranches of samples rather than 11 separate errors.
The automated NA extraction procedure, initially designed for cervical cytology samples,
was amenable to oral wash pellets and<5% showed clogging/blocking on the automated
platform. This level was manageable from a laboratory-process point of view. Quantity of
extracted NA varied according to sample and associated cellularity. Quantitative assessment
of showed that the mean NA yield was 64ng/ul (range 27ng/ul to 130ng/ul). Yield was not
affected according to whether the sample was transported as a postal kit or via the practice
and, as described, was more dependent on the individual sample. Purity of the NA as
Table 6. Follow-up participant characteristics.
Variable Category Follow-up HPV Test % 95% CI
Overall 380 234 61.6 56.6 66.3
Gender Male 154 94 61.0 53.2 68.4
Female 226 140 61.9 55.5 68.0
Age 16–25 39 18 46.2 31.6 61.4
26–39 96 44 45.8 36.2 55.8
40–49 81 49 60.5 49.6 70.4
50–59 83 59 71.1 60.6 79.7
60–69 81 64 79.0 68.9 86.5
SIMD 1 (most deprived) 89 47 52.8 42.5 62.8
2 57 41 71.9 59.2 81.9
3 55 32 58.2 45.0 70.3
4 89 57 64.0 53.7 73.2
5 (least deprived) 86 55 64.0 53.4 73.3
Centre Teaching/outreach 1—Tayside 17 12 70.6 46.9 86.7
GDP 1—Tayside 26 11 42.3 25.5 61.1
GDP 2—Tayside 98 77 78.6 69.5 85.5
Teaching/outreach 1—GG&C 128 72 56.3 47.6 64.5
GDP 1—GG&C 60 36 60.0 47.4 71.4
GDP 2—GG&C 40 21 52.5 37.5 67.1
Teaching/outreach 2—Tayside 11 5 45.5 21.3 72.0
Recruitment model Research Nurse 314 202 64.3 58.9 69.4
Dental Team 66 32 48.5 36.8 60.3
Setting Teaching/outreach 156 89 57.1 49.2 64.6
General Dental Practice (GDP) 224 145 64.7 58.3 70.7
Follow Up Method Appointment 179 155 86.6 80.8 90.8
Post 199 79 39.7 33.2 46.6
Unknown 2 0 0.0 0.0 65.8
doi:10.1371/journal.pone.0165847.t006
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measured by 260/280 absorbance ratios showed between sample variation; however, adequate
quality for the key downstream application [HPV PCR testing] was evidenced by amplification
of the cellular in-house control (beta globin) in 98% of samples.
HPV prevalence and diversity
The present study was not powered to examine HPV prevalence of HPV types including in
subgroups or in relation to risk associations.There were 380 participants with an unequivocal
HPV test result at baseline (Table 7). At baseline, 21 participants were HPV positive, giving a
prevalence of 5.5% (95%CI 3.6%, 8.3%). In relation to the HPV types detected at baseline, 17
samples had mono infections, 4 had dual infections and one contained multiple-infection with
5 types. A total of 14 samples contained at least one high-risk HPV type, whereas 5 samples
contained low-risk types only (3 x HPV 42, 1 x HPV 44, 1 x HPV 42 & 44) and 2 samples types
of intermediate risk (1 x HPV 53, 1 x HPV 66). HPV 16 was the most commonly detected
infection and was evident in 12/17 samples; other HR-HPV types detected were HPV 39, HPV
56, HPV 58 and HPV 59 either as mono infections or as part of a multiple infection.
Oral HPV positivity did not vary with gender but there is a suggestion of an association
with age (p = 0.081) and with deprivation, (p = 0.037). Oral HPV positivity was greatest in the
26–39 age-group where the rate was 10.4% (95%CI 5.8%, 18.1%) compared to a rate of 2.6%
(95%CI 0.1%, 13.2%) in the 16–25 age group.
Out of the 380 who gave a valid oral swab at baseline, 234 had a valid swab at follow-up,
61.6% (95% CI 56.6%, 66.3%). Among those with both a baseline and follow up HPV result, 4
out of 223 HPV negative at baseline acquired HPV, 1.8% (95% CI 0.7%, 4.5%). There were 11
HPV positive individuals at baseline and 8 were clear of HPV at follow-up, giving a clearance
percentage of 72.7% (95% CI 43.3%, 90.3%).
Discussion
In summary, our multidisciplinary research group has demonstrated feasibility of recruiting
participants using dental care facilities, a centralised laboratory (SHPVRL), and data-linkage
Table 7. Oral HPV Prevalence.
Variable Category Total HPV prevalence n % 95% CI
Overall 380 21 5.5 3.6 8.3
Gender Male 154 8 5.2 2.7 9.9
Female 226 13 5.8 3.4 9.6
Age 16–25 39 1 2.6 0.1 13.2
26–39 96 10 10.4 5.8 18.1
40–49 81 5 6.2 2.7 13.6
50–59 83 1 1.2 0.1 6.5
60–80 81 4 4.9 1.9 12.0
SIMD 1 (most deprived) 89 9 10.1 5.4 18.1
2 57 1 1.8 0.1 9.3
3 55 5 9.1 3.9 19.6
4 89 4 4.5 1.8 11.0
5 (least deprived) 86 1 1.2 0.1 6.3
Missing 4 1 25.0 1.3 69.9
HPV Acquisition since baseline 223 4 1.8 0.7 4.5
HPV Clearance since baseline 11 8 72.7 43.4 90.3
doi:10.1371/journal.pone.0165847.t007
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resources, to undertake epidemiological studies of oral HPV infection. The experience and
data gained now make us well placed to design and implement a population study which
would measure the impact of the HPV vaccine on oral HPV among women and assess the
implications for extending the vaccine to boys.
We achieved an overall participation rate of 33.1%, which was somewhat lower than the
67% participation rate in the National Health and Nutrition Survey (NHANES) used in the US
oral prevalence study [10], but is higher than the approximate 10% reported in the Swedish
study [15], and participation rates are unreported in other studies [11, 13, 16]. However, our
recruitment strategy was to opportunistically approach sequential patients attending dental
practices (for the purposes of dental care), while the NHANES study involved targeted
approaches to households and home-based interviews. Lower proportions of younger patients
were recruited than anticipated, despite dental registration being high for this group [21]. The
16–25 year age-group was particularly important given that women from this group will have
had the opportunity for HPV vaccination as part of the national programme. The imbalance of
more female to male patients approached was also interesting. This was similar to data in the
British Household Panel Survey 2008 from Scottish responders, which showed that females
(71%) were more likely to report having a dental check-up than males (63%), and similarly for
NHS dental check-ups: females 54% and males 44% [30]. NHS dental practices in Scotland
seem to be a potentially good way to access representative population. In terms of both their
location and the profile of registered patients—with limited differences by region, age, sex, and
socioeconomic compared to the Scottish population. There is now over 90% of the population
registered in 2014, 70% of whom attended in previous 2 years [21].
The consent rate to the data linkage component (96%) was substantially higher than antici-
pated or observed elsewhere—a systematic review and meta-analysis of the international litera-
ture estimated 67% consent rate to use linkage to medical records [31]. Moreover, the data
linkage could be used to validate self-reported HPV-vaccination history, but with greater detail
on timings and doses available from the linked data than the self-report information.
To our knowledge this was the first observational epidemiological studies in Scotland to
recruit patients through dental settings with support of Research Nurses. While both the
Research Nurses and Dental Teams faced the same challenges in terms of converting patient
approaches to study participants, the Research Nurses were largely able to work more inten-
sively, recruit more participants, and meet their targets on time. Dental Care Teams man-
aged to recruit participants at the same patient participation rate, but were not able to recruit
sufficient numbers in the allotted time-frame. The higher costs for the Research Nurse
model were due to them being employed and their salary costs being paid directly for this
study. They were then deployed to work within the different dental settings. The Dental Care
Teams were fitting this study into their clinical daily practice routine and were compensated
accordingly on an individual participant recruitment basis which was based on payment of
similar tasks on their contract. Completion of the questionnaire on the tablet computer was
disappointingly much lower than anticipated. The reasons were that one centre offered the
paper version as an option rather than as a back-up, and there were technical reasons, mainly
related to internet connectivity issues in two centres, which could be addressed prior to a
larger study.
Postal follow-up, in which patients provided their own oral gargle/rinse specimen and
posted it (with the online/postal questionnaire) was less effective (36.4%) than a follow-up
appointment, However this response was much higher than that observed in an earlier Scottish
survey to facilitate HPV vaccine monitoring where response rate to a self-taken urine or vagi-
nal swab was (13.2%) [32]. It is worth noting that recruitment did not seem to be affected by
the fact that we were not going to feedback HPV test results.
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Participants were able to complete a questionnaire covering a wide-range of factors includ-
ing demographic, socioeconomic, lifestyle, and sexual behaviour/health. While a third of
participants gave feedback that they were uncomfortable with the sexual activity questions,
completion rates were high, and participants were able to disclose risk behaviours. Capture of
this information may have been facilitated by self-completion in a private area or perhaps (for
over a half of participants) by the online questionnaire.
In terms of sexual history, we were able to access a significantly at-risk sample. For exam-
ple, 39% of male participants reported recreational drug use, 34% of males reported >10
partners, 36% of males reported insertive anal sex with a female partner and 24% of women
reported receptive anal sex. The proportions reporting >10 partners is broadly similar to
those reported by the NATSAL study [23]. In addition, 15% of women reported a previous
STI. This risk behaviour profile carried into reported smoking and alcohol intake, with
smoking prevalence (males 26%, females 28%) slightly higher than the Scottish population
(males 25%, females 24%), and alcohol abstinence (males 4%, females 5%) lower than the
Scottish population (males 12%, females 17%) [24]. There were insufficient data to look at
risk associations of sociodemographic and behavioural factors with oral HPV prevalence or
incidence.
Our preliminary estimate of oral HPV prevalence (5.5%; 95%CI 3.6, 8.3) is remarkably in-
keeping with the overall prevalence in the US population (6.9%; 95%CI 5.7, 8.3) [10], and the
pooled estimate from the systematic review and meta-analysis (4.5%; 95%CI 5.7, 4.1) [14]. We
did not have sufficient power in our study to produce precise estimates of prevalence in differ-
ent strata or subgroups, although there was a tendency for higher prevalence in 26–39 years
olds (10.4%; 95%CI 5.8%, 18.1).
Conclusions
Our study demonstrates that it is feasible to investigate the prevalence, incidence, and determi-
nants of oral HPV infection in dental settings. We now know what resources and methods are
needed to expand this approach to assess the impact of the school-based HPV vaccination pro-
gramme in Scotland on oral HPV in girls/women who have received the vaccine and to exam-
ine if there has been any herd immunity in boys/men. Crucially we have sufficient data to
power a full-population approach. We have provided the first preliminary estimate of oral
HPV prevalence in the Scottish population. In our preliminary analysis we found an overall
prevalence of oral HPV infection of 5.5% and a higher prevalence among 26–39 year olds of
10.4%.
We demonstrated that the Research Nurse recruitment model was more effective than Den-
tal Care Teams in terms of baseline and follow-up recruitment and meeting recruitment tar-
gets on time, but that the former model was more expensive.
To undertake a fully powered study to assess the impact of the HPV vaccination pro-
gramme in Scotland on oral HPV infection in men and women, we would need to enhance
recruitment of 16–25 year olds. This could be established in dental settings serving populations
with a high proportion of young people, including community and Further/Higher education
settings.
We have also shown that the boundaries of the nature of research undertaken in dental set-
tings can be stretched beyond current traditional dental care and research remits. This points
to the importance of further research into barriers and facilitators to implement other risk fac-
tor assessment / prevention, screening, and care activities not necessarily associated with cur-
rent practice (eg: smoking/alcohol counselling, diabetes/HIV screening, or further clinical
prevention interventions).
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